Antioxidant enzymatic activities in alzheimer's disease: The relationship to acetylcholinesterase inhibitors

Journal of Alzheimer's Disease

Volumn 30, Issue 3, 2012, Pages 467-474

  Klugman, Anthony ^a   Naughton, Declan P ^b   Isaac, Mokhtar ^a   Shah, Iltaf ^b   Petroczi, Andrea ^b   Tabet, Naji ^a,c  

^a Crowborough Memorial Hospital ^*  (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; antioxidants; catalase; glutathione reductase; oxidative stress

Indexed keywords

ANTIOXIDANT; CATALASE; DONEPEZIL; GALANTAMINE; GLUTATHIONE REDUCTASE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 84862847822     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120124     Document Type: Article

References (44)

1. Coyle JT, Price DL, DeLongMR(1983) Alzheimer's disease: A disorder of cortical cholinergic innervations. Science 219, 1184-1190.
2. Farlow MR (2002) Do cholinesterase inhibitors slow progression of Alzheimer's disease? Int J Clin Pract Suppl 127, 37-44.
3. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 162, 645-647.
4. Zhang HY, Tang XC, Huperzine B (2000) A novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells. Neurosci Lett 292, 41-44.
5. Kimura M, Akasofu S, Ogura H, Sawada K (2005) Protective effect of donepezil against A-(1-40) neurotoxicity in rat septal neurons. Brain Res 1047, 72-84.
6. Wang R, Zhou J, Tang XC (2002) Tacrine attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Brain Res Mol Brain Res 107, 1-8.
7. Saxena G, Patro IK, Nath C (2011) ICV STZ induced impairment in memory and neuronal mitochondrial function: A protective role of nicotinic receptor. Behav Brain Res 224, 50-57.
8. Kamat PK, Tota S, Saxena G, Shukla R, Nath C (2010) Okadaic acid (ICV) induced memory impairment in rats: A suitable experimental model to test anti-dementia activity. Brain Res 1309, 66-74.
9. Tyagi E, Agrawal R, Nath C, Shukla R (2010) Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem Int 56, 135-142.
10. Inanaga K, Ichiki T, Miyazaki R, Takeda K, Hashimoto T, Matsuura H, Sunagawa K (2010) Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein Eknockout mice. Atherosclerosis 213, 52-58.
11. Hwang J, Hwang H, Lee HW, Suk K (2010) Microglia signaling as a target of donepezil. Neuropharmacology 58, 1122-1129.
12. Saxena G, Singh SP, Agrawal R, Nath C (2008) Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 581, 283-289.
13. Sharma B, Singh N, Singh M, Jaggi AS (2008) Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. Pharmacol Biochem Behav 89, 535-545.
14. Melo JB, Sousa C, Garç̃ao P, Oliveira CR, Agostinho P (2009) Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 29, 455-464.
15. Liu X, Xu K, Yan M, Wang Y, Zheng X (2010) Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress. Neurochem Int 57, 588-599.
16. Kumar A, Prakash A, Dogra S (2011) Protective effect of curcumin (Curcuma longa) against D-galactose-induced senescence in mice. J Asian Nat Prod Res 13, 42-55.
17. Kumar P, Kumar A (2009) Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: Possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 615, 91-101.
18. Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, Youdim MB (2008) The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact 175, 318-326.
19. Skoumalov́a A, Ivica J, Santorov́a P, Topinkov́a E, Wilhelm J (2011) The lipid peroxidation products as possible markers of Alzheimer's disease in blood. Exp Gerontol 46, 38-42.
20. Gustaw-Rothenberg K, Kowalczuk K, Stryjecka-Zimmer M (2010) Lipids' peroxidation markers in Alzheimer's disease and vascular dementia. Geriatr Gerontol Int 10, 161-166.
21. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 469, 6-10.
22. Sinem F, Dildar K, G̈okhan E, Melda B, Orhan Y, Filiz M (2010) The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res 7, 463-469.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's Disease. Report of the NINCDS-ADRDAWork Group under the auspices of the department of health and Human Services task Force on Alzheimer's Disease. Neurology 34, 939-944.
24. Hodkinson HM (1972) Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1, 233-238.
25. Francis PT, NordbergA, Arnold SE (2005)Apreclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 26, 104-111.
26. Vural H, Demirin H, Kara Y, Eren I, Delibas N (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol 24, 169-173.
27. Serra JA, Doḿ?nguez RO, Marschoff ER, Guareschi EM, Famulari AL, Boveris A (2009) Systemic oxidative stress associated with the neurological diseases of aging. Neurochem Res 34, 2122-2132.
28. Kharrazi H, Vaisi-Raygani A, Rahimi Z, Tavilani H, Aminian M, Pourmotabbed T (2008) Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. Clin Biochem 41, 932-936.
29. Casado A, Encarnacíon Ĺopez-Ferńandez M, Concepcíon Casado M, de La Torre R (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 33, 450-458.
30. Repetto MG, Reides CG, Evelson P, Kohan S, de Lustig ES, Llesuy SF (1999) Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest 29, 643-649.
31. Perrin R, Briançon S, Jeandel C, Artur Y, Minn A, Penin F, SiestG(1990) Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: A case-control study. Gerontology 36, 306-313.
32. Zafrilla P, Mulero J, Xandri JM, Santo E, Caravaca G, Morillas JM (2006) Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem 13, 1075-1083.
33. Ceballos-Picot I, Merad-Boudia M, Nicole A, Thevenin M, Hellier G, Legrain S, Berr C (1996) Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type-place of the extracellular glutathione peroxidase. Free Radic Biol Med 20, 579-587.
34. Lovell MA, Ehmann WD, Butler SM, MarkesberyWR(1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601.
35. Tabet N, Mantle D, Walker Z, Orrell M (2002) Endogenous antioxidant activities in relation to concurrent vitamins A, C, and E intake in dementia. Int Psychogeriatr 14, 7-15.
36. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV (2000) Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signalling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 176, 53-59.
37. Carvajal FJ, Inestrosa NC (2011) Interactions of AChE with AAggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706. Front Mol Neurosci 4, 19.
38. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) Betaamyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 65, 407-416.
39. Kawamata J, Shimohama S (2011) Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 24(Suppl 2), 95-109.
40. Bailey JA, Ray B, Greig NH, Lahiri DK (2011) Rivastigmine lowers Aand increases sAPPlevels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6, e21954.
41. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405, 458-462.
42. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor7 subunit is an essential regulator of inflammation. Nature 421, 384-388.
43. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J (2004) Cholinergic modulation of microglial activation by7 nicotinic receptors. J Neurochem 89, 337-343.
44. Tabet N (2006) Acetylcholinesterase inhibitors for Alzheimer's disease: Anti-inflammatories in acetylcholine clothing! Age Ageing 35, 336-338.